

[For Immediate Release]



The United Laboratories International Holdings Limited

New Medicine Specializes in Treatment of Influenza Virus Type A Obtained Production Approval

(4 May 2009 – Hong Kong) – The United Laboratories International Holdings Limited (“TUL” or the “Group”; Stock code: 3933), one of the leading pharmaceutical companies in the PRC, announced that the Rimantadine Hydrochloride Granules has recently obtained official production approval from the State Food and Drug Administration of the PRC. Rimantadine Hydrochloride Granules is suitable for the prevention and treatment of influenza virus type A for adults, and also the prevention of infection of influenza virus type A for children.

Mr. Choy Kam Lok, Chairman of TUL, said, “TUL is pleased to obtain the production approval for Rimantadine Hydrochloride Granules at this moment, and we will continue to research and develop new products, and strive to get more new medicines launched to the market.”

-End-

Company Background

Listed on the Stock Exchange of Hong Kong in June 2007, **TUL** is one of the leading pharmaceutical companies in China, principally engaged in the manufacturing and selling of medicines, and the bulk and intermediate products used to produce finished goods. As of 31 December 2008, the Group has a total of 162 products qualified to produce in the PRC and/Hong Kong based on the Drug Registration Approvals in the PRC and Certificates of Drug or Product Registration in Hong Kong, including 40 bulk medicines and 122 finished products.

For further enquiries, please contact:
iPR Ogilvy Ltd.

Sandy Yeung/ Stephanie Yuen / Tina Law / Callis Lau
Tel: (852) 2136 8072/ 3170 6609/ 2136 6181/ 2136 6952
Fax: (852) 3170 6606
E-mail: sandy.yeung@iprogilvy.com/ stephanie.yuen@iprogilvy.com/
tina.law@iprogilvy.com/ callis.lau@iprogilvy.com